Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Oludamilola (Lola) A. Olajide, MD

Advertisement

Articles by Oludamilola (Lola) A. Olajide, MD

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics

ByOludamilola (Lola) A. Olajide, MD
December 5th 2020

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer

ByOludamilola (Lola) A. Olajide, MD
March 18th 2020

Oludamilola (Lola) A. Olajide, MD, discusses managing the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in breast cancer.

Advertisement

Latest Updated Articles

  • Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
    Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer

    March 18th 2020



Advertisement
Advertisement

Trending on OncLive

1

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

2

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

3

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer

4

The OncFive: Top Oncology Articles for the Week of 5/31

5

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us